

TIM-3 Inhibitor - Pipeline Insight, 2022

<https://marketpublishers.com/r/T0A78AC06AD5EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: T0A78AC06AD5EN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "TIM-3 Inhibitor - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in TIM-3 Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

TIM-3 Inhibitor Understanding

TIM-3 Inhibitor: Overview

T-cell immunoglobulin and mucin domain 3 (Tim-3) is an immunoglobulin and mucin domain-containing cell surface molecule. The protein is characterized by a common structural organization consisting of an amino-terminal immunoglobulin variable domain (V domain) with five noncanonical cysteines, a mucin stalk, a transmembrane domain and a cytoplasmic tail. TIM-3 is known to interact with four ligands, galectin-9, phosphatidylserine (PtdSer), CEACAM-1 and HMGB1 (high mobility group box-1). Tim-3 is a checkpoint receptor expressed by a wide variety of immune cells as well as leukemic stem cells. Various preclinical data support the therapeutic modulation of TIM3 in multiple disease contexts including autoimmunity, infection, and cancer. The blocking of Tim-3 and PD-1 together can result in reduced tumor progression in preclinical

models and can improve antitumor T-cell responses in cancer patients.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence TIM-3 Inhibitor R&D. The therapies under development are focused on novel approaches for TIM-3 Inhibitor.

TIM-3 Inhibitor Emerging Drugs Chapters

This segment of the TIM-3 Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

TIM-3 Inhibitor Emerging Drugs

Cobolimab: GlaxoSmithKline

Cobolimab is a novel IgG4 anti-TIM-3 monoclonal antibody. It is under clinical investigation in clinical trial in combination with Dostarlimab and Docetaxel in Advanced Non-small cell lung cancer (NSCLC). By binding to and blocking TIM-3, Cobolimab allows for T-cells to become activated so as to enhance T-cell-mediated attacks on tumors. These attacks reduce their growth.

BMS-986258: Bristol-Myers Squibb

BMS-986258 (anti-TIM-3) is a fully-human monoclonal antibody targeting TIM-3 (T cell immunoglobulin and mucin domain-3). It is the first clinical candidate from the discovery collaboration between Five Prime Therapeutics and BMS that includes targets in three immune checkpoint pathways.

Further product details are provided in the report.....

TIM-3 Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different TIM-3 Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on TIM-3 Inhibitor

There are approx. 15+ key companies which are developing the TIM-3 Inhibitor. The companies which have their TIM-3 Inhibitor drug candidates in the most advanced stage, i.e. Phase III include, Novarits Oncology.

Phases

DelveInsight's report covers around 15+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

TIM-3 Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

TIM-3 Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TIM-3 Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TIM-3 Inhibitor drugs.

TIM-3 Inhibitor Report Insights

TIM-3 Inhibitor Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

TIM-3 Inhibitor Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing TIM-3 Inhibitor drugs?

How many TIM-3 Inhibitor drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for

TIM-3 Inhibitor?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the TIM-3 Inhibitor therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for TIM-3 Inhibitor and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Novartis

GlaxoSmithKline

Roche

Incyte Corporation

Bristol-Myers Squibb

Novartis

Interprotein

TrueBinding

Celgene

Sutro Biopharma

Neologics Bioscience

Symphogen

Key Products

Sabatolimab

Cobolimab

RG-7769

INCAGN 02390

BMS 986258

MAS-825

Research program: anticancer peptide therapeutics

Anti-T-cell immunoglobulin and mucin domain-3 monoclonal antibody

Research program: antibody based therapeutics

NB 002

Sym-023

Contents

- Introduction
- Executive Summary
- TIM-3 Inhibitor: Overview
 - Structure
 - Mechanism of Action
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- TIM-3 Inhibitor – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
 - TIM-3 Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- TIM-3 Inhibitor Collaboration Deals
 - Company-Company Collaborations (Licensing / Partnering) Analysis
 - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
 - Comparative Analysis
- Sabatolimab: Novartis Oncology
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
 - Comparative Analysis
- BMS 986258: Bristol-Myers Squibb
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I)
 - Comparative Analysis
- Sym 023: Symphogen

Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Pre-clinical and Discovery Stage Products
Comparative Analysis
NB 002: Neologics Bioscience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
Comparative Analysis
TIM-3 Inhibitor Key Companies
TIM-3 Inhibitor Key Products
TIM-3 Inhibitor- Unmet Needs
TIM-3 Inhibitor- Market Drivers and Barriers
TIM-3 Inhibitor- Future Perspectives and Conclusion
TIM-3 Inhibitor Analyst Views
TIM-3 Inhibitor Key Companies
Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for TIM-3 Inhibitor
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for TIM-3 Inhibitor
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: TIM-3 Inhibitor - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/T0A78AC06AD5EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T0A78AC06AD5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970